{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:25:32Z","timestamp":1758475532120,"version":"3.38.0"},"reference-count":22,"publisher":"Japanese Society of Internal Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,3,1]]},"DOI":"10.2169\/internalmedicine.3585-24","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T22:15:19Z","timestamp":1740780919000},"page":"717-723","source":"Crossref","is-referenced-by-count":1,"title":["Complete Remission with Nivolumab Monotherapy of Advanced Gastric Neuroendocrine Carcinoma"],"prefix":"10.2169","volume":"64","author":[{"given":"Koichiro","family":"Tajima","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kurashiki Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Shimodate","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kurashiki Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Mouri","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kurashiki Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Nagahisa","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kurashiki Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Nishina","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kurashiki Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motowo","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kurashiki Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. van der Veen A, Seesing MFJ, Wijnhoven BPL, et al. Management of resectable esophageal and gastric (mixed adeno) neuroendocrine carcinoma: a nationwide cohort study. Eur J Surg Oncol 44: 1955-1962, 2018."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kang SH, Kim KH, Seo SH, et al. Neuroendocrine carcinoma of the stomach: a case report. World J Gastrointest Surg 6: 77-79, 2014.","DOI":"10.4240\/wjgs.v6.i4.77"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Okita NT, Kato K, Takahari D, et al. Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma. Gastric Cancer 14: 161-165, 2011.","DOI":"10.1007\/s10120-011-0025-5"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Modlin IM, Lye KD, Kidd M. Carcinoid tumors of the stomach. Surg Oncol 12: 153-172, 2003.","DOI":"10.1016\/S0960-7404(03)00034-3"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 24: 152-160, 2013.","DOI":"10.1093\/annonc\/mds276"},{"key":"6","unstructured":"6. Morizane C, Machida N, Honma Y, et al. Effectiveness of etoposide and cisplatin vs irinotecan and cisplatin therapy for patients with advanced neuroendocrine carcinoma of the digestive system: the TOPIC-NEC phase 3 randomized clinical trial. JAMA Oncol 8: 1447-1455, 2022."},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390: 2461-2471, 2017.","DOI":"10.1016\/S0140-6736(17)31827-5"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Janjigian YY, Bendell J, Calvo E, et al. CheckMate-032 Study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol 36: 2836-2844, 2018.","DOI":"10.1200\/JCO.2017.76.6212"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Sawayama H, Komohara Y, Hirao H, et al. Nivolumab exerts therapeutic effects against metastatic lesions from early gastric adenocarcinoma with a small proportion of neuroendocrine carcinoma after gastrectomy: a case report. Clin J Gastroenterol 13: 759-765, 2020.","DOI":"10.1007\/s12328-020-01159-8"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Yan B, Cui M, You J, et al. Gastric adenocarcinoma is concurrent with metastatic neuroendocrine cancer treated with nivolumab and chemotherapy: a case report. Mol Clin Oncol 9: 607-612, 2018.","DOI":"10.3892\/mco.2018.1740"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Seyama Y, Yamada T, Suzuki H, et al. Gastric neuroendocrine carcinoma presenting complete durable response by nivolumab treatment for multiple metastases and radiotherapy to oligoprogressive metastasis. Int Cancer Conf J 12: 268-273, 2023.","DOI":"10.1007\/s13691-023-00611-z"},{"key":"12","unstructured":"12. TNM Classification of Malignant Tumours. 8th ed. Brierley JD, Gospodarowicz MK, Wittekind C, Eds. Wiley-Blackwell, Hoboken, 2017."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Matsubara Y, Ando T, Hosokawa A, et al. Neuroendocrine carcinoma of the stomach: a response to combination chemotherapy consisting of ramucirumab plus paclitaxel. Intern Med 57: 671-675, 2018.","DOI":"10.2169\/internalmedicine.9369-17"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ready NE, Ott PA, Hellmann MD, et al. Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort. J Thorac Oncol 15: 426-435, 2020.","DOI":"10.1016\/j.jtho.2019.10.004"},{"key":"15","unstructured":"15. Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 22: 51-65, 2021."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Agar C, Geier M, L\u00e9veiller G, et al. Brief report on the efficacy of nivolumab in patients with previously treated advanced large-cell neuroendocrine cancer of the lung. JTO Clin Res Rep 2: 100129, 2020.","DOI":"10.1016\/j.jtocrr.2020.100129"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Fournel L, Wu Z, Stadler N, et al. Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer. Cancer Lett 464: 5-14, 2019.","DOI":"10.1016\/j.canlet.2019.08.005"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Fiorica F, Tebano U, Gabbani M, et al. Beyond abscopal effect: a meta-analysis of immune checkpoint inhibitors and radiotherapy in advanced non-small cell lung cancer. Cancers (Basel) 13: 2352, 2021.","DOI":"10.3390\/cancers13102352"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Saiag P, Molinier R, Roger A, et al. Efficacy of large use of combined hypofractionated radiotherapy in a cohort of anti-PD-1 monotherapy-treated melanoma patients. Cancers (Basel) 14: 4069, 2022.","DOI":"10.3390\/cancers14174069"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol 17: e542-e551, 2016.","DOI":"10.1016\/S1470-2045(16)30406-5"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Kitadai R, Zenke Y, Hishima T, et al. Intracranial complete response for non-small-cell lung cancer patient with negative PD-L1 expression of the lung using nivolumab. Cancer Rep (Hoboken) 5: e1460, 2022.","DOI":"10.1002\/cnr2.1460"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Tamura K, Hasegawa K, Katsumata N, et al. Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: multicenter, open-label phase 2 trial. Cancer Sci 110: 2894-2904, 2019.","DOI":"10.1111\/cas.14148"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/5\/64_3585-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T03:37:24Z","timestamp":1740800244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/5\/64_3585-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3585-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,1]]},"article-number":"3585-24"}}